219 related articles for article (PubMed ID: 20197681)
1. Two newly diagnosed HLA class II-deficient patients identified by rapid vector-based complementation analysis reveal discoordinate invariant chain expression levels.
Schmetterer KG; Seidel MG; Körmöczi U; Rottal A; Schwarz K; Matthes-Martin S; Steinberger P; Pickl WF
Int Arch Allergy Immunol; 2010; 152(4):390-400. PubMed ID: 20197681
[TBL] [Abstract][Full Text] [Related]
2. Correction of defective expression in MHC class II deficiency (bare lymphocyte syndrome) cells by retroviral transduction of CIITA.
Bradley MB; Fernandez JM; Ungers G; Diaz-Barrientos T; Steimle V; Mach B; O'Reilly R; Lee JS
J Immunol; 1997 Aug; 159(3):1086-95. PubMed ID: 9233601
[TBL] [Abstract][Full Text] [Related]
3. Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival.
Souwer Y; Chamuleau ME; van de Loosdrecht AA; Tolosa E; Jorritsma T; Muris JJ; Dinnissen-van Poppel MJ; Snel SN; van de Corput L; Ossenkoppele GJ; Meijer CJ; Neefjes JJ; Marieke van Ham S
Br J Haematol; 2009 May; 145(3):334-43. PubMed ID: 19245431
[TBL] [Abstract][Full Text] [Related]
4. Three novel mutations of the CIITA gene in MHC class II-deficient patients with a severe immunodeficiency.
Dziembowska M; Fondaneche MC; Vedrenne J; Barbieri G; Wiszniewski W; Picard C; Cant AJ; Steimle V; Charron D; Alca-Loridan C; Fischer A; Lisowska-Grospierre B
Immunogenetics; 2002 Feb; 53(10-11):821-9. PubMed ID: 11862382
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N
J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831
[TBL] [Abstract][Full Text] [Related]
6. Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain.
Itoh-Lindstrom Y; Piskurich JF; Felix NJ; Wang Y; Brickey WJ; Platt JL; Koller BH; Ting JP
J Immunol; 1999 Sep; 163(5):2425-31. PubMed ID: 10452977
[TBL] [Abstract][Full Text] [Related]
7. Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL).
Cycon KA; Rimsza LM; Murphy SP
Exp Hematol; 2009 Feb; 37(2):184-194. PubMed ID: 19081173
[TBL] [Abstract][Full Text] [Related]
8. Introduction of exogenous class II trans-activator in MHC class II-deficient ABI fibroblasts results in incomplete rescue of MHC class II antigen expression.
Peijnenburg A; Gobin SJ; van Eggermond MC; Godthelp BC; van Graafeiland N; van den Elsen PJ
J Immunol; 1997 Sep; 159(6):2720-7. PubMed ID: 9300692
[TBL] [Abstract][Full Text] [Related]
9. Discoordinate surface expression of IFN-gamma-induced HLA class II proteins in nonprofessional antigen-presenting cells with absence of DM and class II colocalization.
Muczynski KA; Anderson SK; Pious D
J Immunol; 1998 Apr; 160(7):3207-16. PubMed ID: 9531276
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells.
Satoh A; Toyota M; Ikeda H; Morimoto Y; Akino K; Mita H; Suzuki H; Sasaki Y; Kanaseki T; Takamura Y; Soejima H; Urano T; Yanagihara K; Endo T; Hinoda Y; Fujita M; Hosokawa M; Sato N; Tokino T; Imai K
Oncogene; 2004 Nov; 23(55):8876-86. PubMed ID: 15467734
[TBL] [Abstract][Full Text] [Related]
11. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity.
Sartoris S; Valle MT; Barbaro AL; Tosi G; Cestari T; D'Agostino A; Megiovanni AM; Manca F; Accolla RS
J Immunol; 1998 Jul; 161(2):814-20. PubMed ID: 9670958
[TBL] [Abstract][Full Text] [Related]
12. Conserved residues of the bare lymphocyte syndrome transcription factor RFXAP determine coordinate MHC class II expression.
Long AB; Ferguson AM; Majumder P; Nagarajan UM; Boss JM
Mol Immunol; 2006 Feb; 43(5):395-409. PubMed ID: 16337482
[TBL] [Abstract][Full Text] [Related]
13. Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor.
Mueller RB; Skapenko A; Grunke M; Wendler J; Stuhlmuller B; Kalden JR; Schulze-Koops H
Arthritis Rheum; 2005 Feb; 52(2):451-60. PubMed ID: 15692975
[TBL] [Abstract][Full Text] [Related]
14. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome).
Steimle V; Otten LA; Zufferey M; Mach B
Cell; 1993 Oct; 75(1):135-46. PubMed ID: 8402893
[TBL] [Abstract][Full Text] [Related]
15. Discoordinate expression of invariant chain and MHC class II genes in class II transactivator-transfected fibroblasts defective for RFX5.
Peijnenburg A; Van Eggermond MJ; Gobin SJ; Van den Berg R; Godthelp BC; Vossen JM; Van den Elsen PJ
J Immunol; 1999 Jul; 163(2):794-801. PubMed ID: 10395672
[TBL] [Abstract][Full Text] [Related]
16. Regulation of genes for HLA class II antigens in cell lines from patients with severe combined immunodeficiency.
de Préval C; Hadam MR; Mach B
N Engl J Med; 1988 May; 318(20):1295-300. PubMed ID: 3129659
[TBL] [Abstract][Full Text] [Related]
17. Novel mutations within the RFX-B gene and partial rescue of MHC and related genes through exogenous class II transactivator in RFX-B-deficient cells.
Nagarajan UM; Peijnenburg A; Gobin SJ; Boss JM; van den elsen PJ
J Immunol; 2000 Apr; 164(7):3666-74. PubMed ID: 10725724
[TBL] [Abstract][Full Text] [Related]
18. Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells.
Croce M; De Ambrosis A; Corrias MV; Pistoia V; Occhino M; Meazza R; Giron-Michel J; Azzarone B; Accolla RS; Ferrini S
Oncogene; 2003 Oct; 22(49):7848-57. PubMed ID: 14586411
[TBL] [Abstract][Full Text] [Related]
19. CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant.
Zhou H; Su HS; Zhang X; Douhan J; Glimcher LH
J Immunol; 1997 May; 158(10):4741-9. PubMed ID: 9144488
[TBL] [Abstract][Full Text] [Related]
20. Combined immunodeficiency with defective expression in MHC class II genes.
Griscelli C; Lisowska-Grospierre B; Mach B
Immunodefic Rev; 1989; 1(2):135-53. PubMed ID: 2517209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
